Drug Profile


Alternative Names: AD-810; AD-810N; CI-912; Excegran; Kinaplase; PD-110843; Tremode; Trerief; Zonegran

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Concordia Pharmaceuticals; Dainippon Sumitomo Pharma; Eisai Co Ltd; Sumitomo Dainippon Pharma
  • Class Antiepileptic drugs; Isoxazoles
  • Mechanism of Action Antioxidants; Calcium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy; Parkinson's disease
  • Phase III Lewy body disease
  • Discontinued Cerebral ischaemia; Manic episodes; Migraine; Neuropathic pain; Obesity

Most Recent Events

  • 01 Dec 2016 Dainippon Pharmaceutical initiates enrolment in a phase III trial for Parkinson's disease in Japan (UMIN000024859)
  • 08 Nov 2016 Launched for Epilepsy (Adjunctive treatment, In adolescents, In children) in Oceania, Africa, Middle East, Russia (PO)
  • 08 Nov 2016 Launched for Epilepsy (Monotherapy, Newly diagnosed) in Russia, Oceania, Africa, Middle East (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top